Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea joint statement by the german society for gynecological

Authors

  • T. Rabe Университетская клиника г. Гейдельберга, Германия, Germany
  • H.-J. Ahrendt практика акушерства, г. Магдебург, Германия, Germany
  • C. Albring Профессиональная ассоциация гинекологов Германии, Germany
  • J. Bitzer Университетская больница г. Базель, Швейцария, Switzerland
  • P. Bouchard госпиталь Сент Антуана, Париж, Франция, France
  • U. Cirkel Клиника г. Минден, Германия, Germany
  • C. Egarter Университет г. Вены, Австрия, Austria
  • K. König
  • W. Harlfinger Профессиональная ассоциация гинекологов Германии, Germany
  • M. Matzko Клиника г. Дахау, Германия, Germany
  • A. O. Mueck Университетская клиника г. Тюбинген, Германия, Germany
  • T. Römer Протестантская больница г. Kельн, Германия, Germany
  • T. Schollmeyer Университет г. Киль, Германия, Germany
  • P. Sinn Институт патологии, г. Гейдельберг, Германия, Germany
  • T. Strowitzki Университетская клиника г. Гейдельберга, Германия, Germany
  • H.-R. Tinneberg Университетская клиника гг. Гиссен и Марбург, Германия, Germany
  • M. Wallwiener Университетская клиника г. Гейдельберга, Германия, Germany
  • R. L. De Wilde Клиника гинекологии, акушерства и гинекологии онкологии, г. Ольденбург, Германия, Germany

DOI:

https://doi.org/10.18370/2309-4117.2014.15.61-63

Keywords:

leiomyomas, uterine fibroids, menorrhagia, treatment options, ulipristal acetate, GnRH analogues, steroid hormones

Abstract

Approximately 24 million European and more than 20 million North American women between the ages of 35 and 55 are suffering from uterine fibroids, i.e. 40% of all women in this age group are affected. The symptoms are excessive uterine bleeding, anaemia, pain and infertility. Many women find their quality of life severely compromised, and this leads to hysterectomy in many cases. So far there has been no effective and well-tolerated drug. The only approved drugs for the treatment of symptomatic uterine fibroids are GnRH agonists, but their use is relatively limited because of severe side effects due to the resulting low levels of estrogen causing hot flushes, depression, mood swings, loss of libido, vaginitis and loss of bone mineral density. As fibroid growth is dependent on progesterone, progesterone receptor modulators have proven effective in pilot studies. Two randomised double-blind studies have shown the effectiveness of the progesterone receptor modulator ulipristal acetate in the preoperative treatment of leiomyomas and the control of concomitant menorrhagia. No significant side effects have occurred under a dosage of 5 and 10 mg UPA over 3 months. A cessation of menorrhagia was observed after only 7 days, and a volume reduction of the uterine fibroids by 40% was achieved within 3 months and seemed to persist even 6 months after discontinuing the drug. A preparation with a dosage of 5 mg ulipristal acetate is available as Esmya from the spring of 2012 for the preoperative treatment of leiomyomas.

Author Biographies

C. Egarter, Университет г. Вены, Австрия

кафедра акушерства

M. Matzko, Клиника г. Дахау, Германия

отделение радиологии

A. O. Mueck, Университетская клиника г. Тюбинген, Германия

центр акушерства

T. Schollmeyer, Университет г. Киль, Германия

отделение акушерства и гинекологии

References

  1. Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 10.
  2. Becker ER, Spalding J, DuChane J, Horowitz IR Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998–2002. J Natl Med Assoc 2005; 97: 1336–42.
  3. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA et al. Variation in the incidence of uterine leiomyoma among premenopausal women byage and race. Obstet Gynecol 1997; 90: 967–73.
  4. Vollenhoven B. Introduction: the epidemiology of uterine leiomyomas. Baillieres Clin Obstet Gynaecol 1998; 12: 169–76.
  5. Cramer SF, Patel A The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435.
  6. Christiansen JK The facts about fibroids. Presentation and latest management options. Postgrad Med 1993; 94: 129–37.
  7. Matchar DB, Myers ER, Barber MW, Couchman GM, Datta S, Gray RN et al. Management of uterine fibroids. Evid Rep Technol Assess (Summ) 2001; 34: 1–6.
  8. Sato F, Miyake H, Nishi M, Kudo R Fertility and uterine size among Asian women undergoing hysterectomy for leiomyomas. Int J Fertil Womens Med 2000; 45: 34–7.
  9. Chen CR, Buck GM, Courey NG, Perez KM, Wactawski-Wende J Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001; 153: 20–6.
  10. Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006; 108: 930–7.
  11. Faerstein E, Szklo M, Rosenshein N Risk factors for uterine leiomyoma: a practicebased case-control study. I. African- American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001; 153: 1–0.
  12. Baird DD, Schectman JM, Dixon D, Sandler DP, Hill MC African Americans at higher risk than whites for uterine fibroids: ultrasound evidence. Am J Epidemiol 1998; 147: S90.
  13. Huyck KL, Panhuysen CI, Cuenco KT, Zhang J, Goldhammer H, Jones ES, Somasundaram P, Lynch AM, Harlow BL, Lee H, Stewart EA, Morton CC The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol 2008; 198: 168.e1.
  14. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41: 483.
  15. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB Hysterectomy in the United States, 1988–1990. Obstet Gynecol 1994; 83: 549.
  16. Mecke H, Wallas F, Brocker A, Gertz HP Pelviscopic myomas enucleation: technique, limits, complications. Geburtsh Frauenheilkd 1995; 55: 374–9.
  17. Lumsden MA Embolization versus myomectomy versus hysterectomy: which is best,when? Hum Reprod 2002; 17: 253–9.
  18. Hirsch HA, Käser O, Iklé FA Atlas der gynäkologischen Operationen, 6. Aufl.; Thieme, Stuttgart, New York, 1999.
  19. Jones MW, Norris HJ Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 1995; 14: 243–9.
  20. Mittal KR, Chen F, Wei JJ, Rijhvani K, Kurvathi R, Streck D, Dermody J et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyomalike areas. Modern Pathology 2009; 22: 1303–11.
  21. Friedrich M, Villena-Heinsen C, Mink D, Hell K, Schmidt W Leiomyosarcomas of the female genital tract: a clinical and histopathological study. Eur J Gynaecol Oncol 1998; 19: 470–5.
  22. Harlow BL, Weiss NS, Lofton S The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76: 399–402.
  23. Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours. IARC Press, Lyon; 2003.
  24. Laughlin SK, Schroeder JC, Baird DD New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010; 28: 204–17.
  25. Arici A, Sozen I Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril 2000; 73: 1006–11.
  26. Chavez NF, Stewart EA Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001; 44: 372–84.
  27. Luo X, Ding L, Xu J, Chegini N Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005; 146: 1097–18.
  28. Martin Chaves EB, Brum IS, Stoll J, Capp E, Corleta HE Insulin-like growth factor 1 receptor mRNA expression and autophosphorylation in human myometrium and leiomyoma. Gynecol Obstet Invest 2004; 57: 210–3.
  29. Fields KR, Neinstein LS Uterine myomas in adolescents: case reports and a review of the literature. J Pediatr Adolesc Gynecol 1996; 9: 195–8.
  30. Cramer SF, Patel A The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435–8.
  31. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986; 293: 359–62.
  32. Lumbiganon P, Rugpao S, Phandhu-Fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y Protective effect of depotmedroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case-control study. Br J Obstet Gynaecol 1996; 103: 909–14.
  33. Marshall LM, Spiegelman D, Goldman MB et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432–9.
  34. Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P Reproductive factors and risk of uterine fibroids. Epidemiology 1996; 7: 440–2.
  35. Burbank F Childbirth and myoma treatment by uterine artery occlusion: do they share a common biology? J Am Assoc Gynecol Laparosc 2004; 11: 138–52.
  36. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100–7.
  37. Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasoundscreening study. Obstet Gynecol 2009; 113: 630–5.
  38. Okolo S Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 571–88.
  39. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252–5.
  40. Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2011.
  41. Chiaffarino F, Parazzini F, La Vecchia C et al. Use of oral contraceptives and uterine fibroids: results from a casecontrol study. Br J Obstet Gynecol 1999; 106: 857–60.
  42. Common AA, Mocarski EJ, Kolin A, Pron G, Soucie J Therapeutic failure of uterine fibroid embolization caused by underlying leiomyosarcoma. J Vasc Interv Radiol 2001; 12: 1449–52.
  43. Parker WH, Fu YS, Berek JS Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83: 414–8.
  44. Gambone JC, Reiter RC, Lench JB, Moore JG The impact of a quality assurance process on the frequency and confirmation rate of hysterectomy. Am J Obstet Gynecol 1990; 163: 545–50.
  45. Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med 2007; 49: 493–506.
  46. Haney AF Clinical decision making regarding leiomyomata: what we need in the next millennium. Environ Health Perspect 2000; 108: 835–9.
  47. Divakar H Asymptomatic uterine fibroids. Best Practice & Research Clinical Obstetrics and Gynecology 2008; 22: 643–54.
  48. Donnez J, Jadoul P What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002; 17: 1424–30.
  49. Viswanathan M, Hartmann K, McKoy N et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007: 1–122.
  50. Hoekstra AV, Sefton EC, Berry E et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009; 94: 1768–74.
  51. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70: 1722–30.
  52. Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K Laparoscopic myomectomy fertility results. Ann N Y Acad Sci 2001; 943: 269–75.
  53. Marret H, Fauconnier A, Chabbert-Buffet N et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010; 152: 133–7.
  54. Miller CE Unmet Therapeutic Needs for Uterine Myomas. J Minim Invasive Gynecol 2009;
  55. : 11–21.
  56. Lethaby A, Vollenhoven B Fibroids (uterine myomatosis, leiomyomas). Clin Evid (Online) 2011; 11; 2011. pii: 0814.
  57. Statistisches Bundesamt. Diagnosedaten der Krankenhauspatientinnen und patienten (einschl. Sterbe- und Stundenfälle) 2000. Statistisches Bundesamt, Wiesbaden, 2004.
  58. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26: 423–38.
  59. Kovacs KA, Lengyel F, Kornyei JL et al. Differential expression of Akt/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium. J Steroid Biochem Mol Biol 2003; 87: 233–40.
  60. Brandon DD, Bethea CL, Strawn EY et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 169: 78–85.
  61. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160: 637–41.
  62. Tiltman AJ The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 1985; 4: 89–96.
  63. Matsuo H, Maruo T, Samoto T Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997; 82: 293–9.
  64. Maruo T, Matsuo H, Shimomura Y et al. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 2003; 68: 817–24.
  65. Chegini N, Ma C, Tang XM, Williams RS Effects of GnRH analogues, «add-back» steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-â expression. Mol Hum Reprod 2002; 8: 1071–8.
  66. Xu Q, Takekida S, Ohara N et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly (adenosine 52-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005; 90: 953–61.
  67. Chen W, Ohara N, Wang J et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006; 91: 1296–304.
  68. Sasaki H, Ohara N, Xu Q et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007; 92: 616–23.
  69. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999; 14: 2844–50.
  70. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70: 1722–30.
  71. Carr BR, Marshburn PB, Weatherall PT et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76: 1217–23.
  72. Ross RK, Pike MC, Vessey MP et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986; 293: 359–62.
  73. Sayed GH, Zakhera MS, El-Nashar SA, Shaaban MM A randomized clinical trial of a levonorgestrelreleasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet 2011; 112: 126–30.
  74. Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM Intrauterine deviceuse among women with uterine fibroids: a systematic review. Contraception 2010; 82: 41–55.
  75. Lahteenmaki P, Haukkamaa M, Puolakka J et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 1122–6.
  76. Hurskainen R, Teperi J, Rissanen P et al. Quality of life and cost-effectiveness of levonorgestrelreleasing intrauterine system versus hysterectomy for treatment of rnenorrhagia; a randomised trial. Lancet 2001; 357: 273–7.
  77. Goni AZ, Lacruz RL, Paricio JJ, Hernandez Rivas FJ The evonorgestrel intrauterine system as an alternative to hysterectomy for the treatment of idiopathic menorrhagia. Gyn Endocrinol 2009; 25: 581–6.
  78. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Sirkku V, Yliskoski M, Paavonen J Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia. JAMA 2004; 291: 1503–4.
  79. Lethaby A, Vollenhoven B, Sowter M Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001: CD000547.
  80. Donnez J, Tatarchuk TT, Bouchard P, Puscasiu L, Nataliya F, Zakharenko T et al. For the PEARL I Study Group Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
  81. Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F et al. For the PEARL II Study Group Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421–32.
  82. Filicori M, Hall DA, Longhlin JS et al. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormon analogue. Am J Obs tet Gynecol 1983; 147: 726–7.
  83. Maheux R, Guilloteau C, Lemay A et al. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive LHRH agonist treatment: preliminary report. Fertil Steril 1984; 42: 644–6.
  84. Friedman AJ, Barbieri RL, Benacerraf BR Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987; 48: 560–4.
  85. Schlaff WD, Zerhouni EA, Huth JA et al. A placebo controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol 1989; 74: 856–62.
  86. Stovall TG, Muneyyirci-Delale O, Summit RL Jr, Scialli AR GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet Gynecol 1995; 86: 65–71.
  87. Friedman AJ, Daly M, Juneau-Norcross M, Fine C, Rein MS, LeBoff M Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprorelide acetate depot plus either oestrogen-progestin or progestin «add-back» for 2 years. Hum Reprod 1994; 9: 1618–25.
  88. Matta WH, Shaw RW, Nye M Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989; 96: 200–6.
  89. Shaw RW Gonadotrophin hormonereleasing hormone analogue treatment of fibroids Baillière’s. Clin Obstet Gynaecol 1998; 12: 245–68.
  90. Hornstein MD, Surrey ES, Weisberg GW, Casino LA Leuprolide acetate depot and hormonal addback in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91: 16–24.
  91. Palomba S, Affinito P, Tommaselli GA, Nappi C A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70: 111–8.
  92. Palomba S, Orio F Jr, Russo T et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 2004; 19: 1308–14.
  93. Gonzalez-Barcena D, Alvarez RB, Ochoa EP et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997; 12:2028–35.
  94. Levens ED, Potlog-Nahari C, Armstrong AY et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008; 111: 1129–36.
  95. Nieman LK, Blocker W, Nansel T et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebocontrolled, phase IIb study. Fertil Steril 2011; 95: 767.e1–772.e1.
  96. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11: 293–307.
  97. Spitz IM Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003; 68: 981–93.
  98. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005; 12:227–33.
  99. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108: 1381–7.
  100. Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008; 112: 1029–36.
  101. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K Lowdose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust NZ J Obstet Gynaecol 2009; 49: 77–83.
  102. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S,Fiscella K Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009; 146: 215–8.
  103. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K Mifepristone for treatment of uterine leiomyoma: a prospective randomized placebo controlled trial. Hum Reprod 2009; 24: 1870–9.
  104. Feng C, Meldrum S, Fiscella K Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet 2010; 109: 121–4.
  105. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129–36.
  106. Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, doubleblind, placebo controlled, phase IIb study. Fertil Steril 2011; 95: 767–72.
  107. Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007; 87: 1399–412.
  108. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008; 93: 4664–71.
  109. Wiehle R, Goldberg J, Brodniewicz T, Jarus-Dziedzic K, Jabiry-Zieniewicz Z Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstetr Gynaecol 2008; 3: 17–20.173. Spitz IM Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009; 21: 318–24.
  110. Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21: 591–8.
  111. Ioffe OB, Zaino RJ, Mutter GL Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009; 22: 450–9.
  112. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002; 188: 111–23.
  113. Attardi BJ, Burgenson J, Hild SA, Reel JR In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 2004; 88: 277–88.
  114. Gainer EE, Ulmann A Pharmacologic properties of CDB(VA)-2914. Steroids 2003; 68: 1005–11.
  115. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitaryovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92: 3582–9.
  116. Yoshida S, Ohara N, Xu Q et al. Celltype specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260–73.
  117. Musallam Khaled M, Tamim HM, Richards T, Spahn R, Rosendaal FR, Habbal A et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. The Lancet, DOI: 10.1016/S0140-6736(11)61381-0.
  118. De Falco M, Staibano S, Mascolo M, Mignogna C, Improda L, Ciociola F, Carbone IF, Di Lieto A Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes. Eur J Obstet Gynecol Reprod Biol 2009; 144: 44–7.
  119. Kanaoka Y, Hirai K, Ishiko O Microwave endometrial ablation for an enlarged uterus. Arch Gynecol Obstet 2002; 269: 39–42.
  120. Cook JR, Franzo G, Seman EI Pregnancy following endometrial ablation: case history and literature review. Obstet Gynecol Survey 2003; 58: 551–6.
  121. Magos A, O’Connor H Endometriumresektion, Operationstechnik. In: Die endoskopischen Operationen in der Gynäkologie. Urban & Fischer, München-Jena, 2000; 418–26.
  122. Pinion SB, Parkin DE, Abramovich DR, Naji A, Alexander DA, Russell IT Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. Br Med J 1994; 309: 979–83.
  123. O’Connor H, Broadbent JA, Magos AL, McPherson K Medical Research Council randomised trial of endometrial resection versus hysterectomy in management of menorrhagia. Lancet 1997; 349: 897–901.
  124. Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH et al. Hysterectomy, endometrial destruction and Mirena for heavy menstrual bleeding: a systematic review and individual patient data meta-analysis. Br Med J 2010; 341: c3929.
  125. Overton C, Hargreaves J, Maresh M A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study Minimally Invasive Surgical Techniques – Laser, EndoThermal or Endoresection. Br J Obstet Gynaecol 1997; 104: 1351–9.
  126. Onofriescu M New endometrial ablation techniques in the treatment of dysfunctional uterine bleeding. Rev Med Chir Soc Med Nat Iasi 2004; 108: 224–9.
  127. Cooper K, Lee A, Chien P, Raja E, Timmaraju V, Bhattacharya S Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of hospital episode statistics in Scotland. BJOG 2011; 118: 1171–9.
  128. Uhl B Eingriffe am Uterus. In: OP-Manual Gynäkologie und Geburtshilfe. Thieme, Stuttgart, New York 2004; 150–201.
  129. Reid PC Endometrial ablation in England – coming of age? An examination of hospital episode statistics 1989/1990 to 2004/2005. Eur J Obstet Gynecol Reprod Biol 2007; 135: 191–4.
  130. Lethaby A, Hickey M, Garry R Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;4: CD001501.
  131. Shaamash AH, Sayed EH Prediction of successful menorrhagia treatment after thermal ballon endometrial ablation. Obstet Gynaecol Res 2004; 3: 210–6.
  132. Hucke J Alternative Methoden der Endometriumablation. In: Eckstein J, Hucke J (Hrsg). Die endoskopische Operationen in der Gynäkologie. Urban & Fischer, München-Jena, 2000; 438–47.
  133. Lethaby A, Hickey M, Garry R, Penninx J Endometrial resection/ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD001501.
  134. Lethaby A, Augood C, Duckitt K, Farquhar C Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007 Oct 17; (4): CD000400.
  135. Scialli AR, Jestila KJ Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril 1995; 64: 313–20.
  136. Lethaby A, Irvine G, Cameron I Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008 Jan 23; (1): CD001016.
  137. Frishman GN, Jurema MW Myomas and myomectomy. J Minim Invasive Gynecol 2005; 12: 443–56.
  138. Friedman AJ, Thomas PP Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 1995; 85: 631–5.
  139. Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E The levonorgestrel releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 2012; 285: 117–21.
  140. Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011; 83: 48–54.
  141. Milsom I, Andersson K, Andersch B, Rybo G A comparison of flurbiprofen, tranexamic acid, and a levonorgestrelreleasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–88.
  142. Römer T Erfahrungen und Empfehlungen zur Anwendung des Levonorgestrel Intrauterinsystems. Thieme Praxis Report 2009; 1: 1–24.
  143. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18: 75–80.
  144. Chi C, Huq FY, Kadir RA Levonorgestrel-releasing intrauterine system for the management of heavy mestrua bleeding in women with inherited bleeding disorders: long-term followup. Contraception 2011; 83: 242–7.
  145. Lukes AS, Reardon B, Arepally G Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008; 90: 673–7.
  146. Marjoribanks J, Lethaby A, Farquhar C Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006 Apr 19; (2): CD003855.
  147. Higham JM, O’Brien PM, Shaw RW Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 7349.
  148. van Dongen H, Janssen CA, Smeets MJ, Emanuel MH, Jansen FW The clinical relevance of hysteroscopic polypectomy in premenopausal women with abnormal uterine bleeding. BJOG 2009; 116: 1387–90.
  149. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144: 35–42.
  150. Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol 2011; 42: 947–53.
  151. Clarke B, McCluggage WG Iatrogenic lesions and artefacts in gynaecological pathology. J Clin Pathol. 2009; 62: 104–12.

Downloads

Published

2014-07-10

How to Cite

Rabe, T., Ahrendt, H.-J., Albring, C., Bitzer, J., Bouchard, P., Cirkel, U., Egarter, C., König, K., Harlfinger, W., Matzko, M., Mueck, A. O., Römer, T., Schollmeyer, T., Sinn, P., Strowitzki, T., Tinneberg, H.-R., Wallwiener, M., & De Wilde, R. L. (2014). Ulipristal acetate for symptomatic uterine fibroids and myoma-related hypermenorrhea joint statement by the german society for gynecological. REPRODUCTIVE ENDOCRINOLOGY, (15), 61–63. https://doi.org/10.18370/2309-4117.2014.15.61-63

Issue

No. 15 (2014)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2014 T. Rabe, H.-J. Ahrendt, C. Albring, J. Bitzer, P. Bouchard, U. Cirkel, C. Egarter, K. König, W. Harlfinger, M. Matzko, A. O. Mueck, T. Römer, T. Schollmeyer, P. Sinn, T. Strowitzki, H.-R. Tinneberg, M. Wallwiener, R. L. De Wilde

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.